Webpage

Project Code: PNRR-III-C9-2022-I8-186

Project Title: Targeting Cardiac Fibrosis in Heart Failure; Challenges and Potential Solutions Based on ncRNA Therapeutics

Contract number: 760062/23.05.2023

Coordinator: Dr. Fabio Martelli

Labs involved in project implementation:

• Laboratory of Stem Cell Biology

• Laboratory of Inflammation Research

Budget: 1.400.000 Euro

Implementation period: 18.07.2023 – 31.06.2026

Project's code: PN-III-P4-ID-PCE-2020-1340

Project's title: Fundamental mechanisms of post-infarction remodeling in old heart at fibroblast population level

Contract number: PCE122/12.02.2021

Coordinator: Alexandrina Burlacu

Team members: Evelyn Gabriela Rusu, Catalina Marinescu, Mihai Bogdan Preda

Budget: 1.197.912 Lei

Period: 04.01.2021 – 31.12.2023

Project's code: PN-III-P1-1.1-TE-2019-1893

Project's title: MIR-210 genomic locus at the overlap between hypoxia signalling and inflammatory networks

Contract number: TE186/07.01.2021

Coordinator: Dr. Mihai Bogdan Preda

Budget: 431.900 Lei

Period: 07.01.2021 – 31.12.2022

Project's code: PN-III-P4-ID-PCCF-2016-0172

Project's title: Targeting innate immune mechanisms to improve risk stratification and to identify future therapeutic options in myocardial infarction

Contract number: 05/18.07.2018

Coordinator: Acad.Maya Simionescu

Research Partners:

CO: Institute of Cellular Biology and Pathology "Nicolae Simionescu", BUCHAREST

P1: University of Medicine, Pharmacy, Science and Technology, TARGU MURES

P2: University of Medicine and Pharmacy "Carol Davila" BUCHAREST

Budget: 8.500.000 Lei

Period: 18.07.2018 – 31.06.2022

Project's code: POC-A.1-A.1.1.4-E-2015, ID: P_37_668

​Project co-funded by The European Regional Development Fund through the Competitiveness Operational Programme 2014-2020.

Priority Axis 1 - "Research, technological development and innovation (RDI) in support of economic competitiveness and business development".

Action 1.1.4: Attracting personnel with advanced skills from abroad to strengthen the research-development capacity

​Project's title: The improvement of the institutional competitiveness in the treatment of type 1 diabetes by developing an innovative concept of immunotherapy based on mesenchymal stromal cells

​Contract number: 118/16.09.2016

​Coordinators:

Dr. Alexandrina Burlacu (LSCB, ICBP, Romanian Academy, Romania)

Dr. Nadir Askenasy (Frankel Laboratory, Centre for Stem Cell Research, Schneider Children’s Medical Centre of Israel)

​Budget: 8,630,843.2 Lei

​Period: 04.01.2016 – 31.12.2020

Transnational Research Projects on Cardiovascular Diseases 

EXPERT was an interdisciplinary 3-year program involving 6 European nations exploiting the power of RNA biology to fight age-related heart failure (HF). EXPERT will identify pathways characteristic of age-related HF and will abandon the traditional focus on protein-coding genes, instead exploring the non-coding RNA (ncRNA)-mediated regulatory pathways of the human genome. EXPERT uses innovative in vitro/in vivo genetic models, ncRNA gender-specific diagnostic and therapeutic approaches, and clinical/population-based cohorts to explore age-related HF. The project will lead to novel diagnostic and therapeutic strategies for the treatment of HF in the elderly.

EXPERT will a) validate pathways of pathologic cardiac ageing to develop therapeutic ncRNA-based strategies, b) identify an age-specific pattern of circulating ncRNA to predict future cardiac events/death.

The specific objectives were to:

• Generate a cell-type specific ncRNA blueprint of the ageing heart.

• Study ncRNA regulation in cardiac ageing upon interference with cardiac stress leading to HF.

• Validate important age-related cardiovascular pathways by testing ncRNA interventions in small and large animal models.

• Define the predictive value of circulating age-related ncRNA patterns in clinical and population-based cohorts.

 Participants:

(i)  Dr. Thomas THUM, Hannover Medical School, GERMANY;

(ii) Dr. Leon DE WINDT, Maastricht University, NETHERLANDS;

(iii) Dr. Gianluigi CONDORELLI, Humanitas Research Hospital, Milan, ITALY;

(iv) Dr. Valentin FUSTER and Dr. Vicente ANDRES, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, SPAIN;

(v) Dr. Faiez ZANNAD, University of Lorraine, Inserm-CHU of Nancy, FRANCE;

(vi) Dr.  Alexandrina BURLACU, Institute of Cellular Biology and Pathology “Nicolae Simionescu”, Bucharest, ROMANIA.

• Consolidating the subcutaneous transplantation of MSC as a warranted therapy for myocardial infarction, 2017-2018, (Eur 60,000)